A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2015
At a glance
- Drugs XL 999 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Symphony Evolution
- 23 Feb 2010 Planned end date (Nov 2006) added as reported by ClinicalTrials.gov.
- 16 Feb 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 Feb 2010 Symphony Evolution added as trial sponsor and trial affiliate as reported by ClinicalTrials.gov.